Dermavant announced the FDA approval for VTAMA® (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults. This is the first topical novel chemical entity launched for psoriasis in the U.S. in 25 years.

Bristol Myers Squibb (BMS) announced new two-year data that reinforces the durable efficacy and consistent safety profile of Deucravacitinib when used to treat moderate to severe plaque psoriasis.

IPC is pleased to welcome AnaptysBio as a Bronze Level Corporate Member!

Amgen presents new data on the efficacy of apremilast in patients with mild to moderate plaque psoriasis and in patients with palmoplantar pustulosis.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the initiation of VISIBLE. VISIBLE is a first-of-its-kind, large-scale prospective clinical study dedicated to generating key disease insights among Black, Hispanic, Asian, Indigenous, and other people of color.

The U.S. Food and Drug Administration (FDA) has approved a second indication for SKYRIZI® (risankizumab-rzaa) to treat adults with active psoriatic arthritis.

IPC is pleased to welcome Arcutis Biotherapeutics, Inc. as a Bronze Level Corporate Member!

The FDA has approved Otezla® (apremilast) for the treatment of adult patients with plaque psoriasis.

The FDA has granted priority review for spesolimab for the treatment of generalized pustular psoriasis flares.

The European Commission has approved SKYRIZI® for the treatment of active psoriatic arthritis in adults.